查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球霍乱疫苗市场：增长、未来展望、竞争分析 (2022-2030)
市场调查报告书
商品编码
1167479

全球霍乱疫苗市场：增长、未来展望、竞争分析 (2022-2030)

Cholera Vaccines Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格

全球霍乱疫苗市场规模在预测期内将以 10% 的复合年增长率显着增长，原因是各国政府加强了免疫计划的力度以及霍乱发病率上升，尤其是在亚洲和非洲的新兴国家。预计增长.

按产品划分，Dukoral 在 2021 年拥有最大的市场份额，这归因于多种因素，包括它是欧洲、加拿大和澳大利亚旅行者唯一可获得许可的霍乱疫苗。我拥有 另一方面，政府建议 18 至 64 岁前往霍乱疫区的旅行者使用 Vaxchora，它是美国唯一可用的霍乱疫苗，并在全球范围内获得许可。因为它是目前仅提供单剂量霍乱疫苗，预计在预测期内将出现显着增长。

按地区划分，亚太地区被认为是最大的霍乱疫苗市场。 市场增长的驱动因素包括大量霍乱患者、对医疗保健日益增长的兴趣以及政府的治疗和宣传计划举措。 另一方面，北美预计在预测期内增长最快。

本报告按产品和地区分析了全球霍乱疫苗市场，包括市场基本结构、宏观和微观环境因素、整体市场规模趋势展望（2020-2030 年）。详细趋势、主要市场主要参与者的驱动因素和限制因素、概况和增长战略等。

内容

第一章介绍

第 2 章执行摘要

第 3 章霍乱疫苗市场：竞争分析

  • 霍乱疫苗市场：主要供应商的市场定位
  • 供应商在霍乱疫苗市场采用的策略
  • 主要行业战略
  • 层次分析 (2021/2030)

第 4 章霍乱疫苗市场：宏观分析和市场动态

  • 介绍
  • 世界霍乱疫苗市场规模（单位：百万美元，2020-2030 年）
  • 市场动态
    • 市场驱动力
    • 市场製约因素
    • 主要问题
    • 主要机会
  • 促进因素和抑制因素的影响分析
  • 跷跷板分析

第 5 章霍乱疫苗市场：按产品分类（单位：百万美元，2020-2030 年）

  • 市场概览
  • 增长和收益分析 (2021/2030)
  • 市场细分
    • 杜科拉尔
    • 尚哲
    • Vaxchora
    • 其他

第 6 章北美霍乱疫苗市场，2020-2030 年，美元（百万）

  • 市场概览
  • 霍乱疫苗市场：按产品分类，2020-2030 年，美元（百万）
  • 霍乱疫苗市场：按地区划分，2020-2030 年，美元（百万）
    • 北美

第7章英国和欧盟国家的霍乱疫苗市场（单位：百万美元，2020-2030）

第八章亚太霍乱疫苗市场（单位：百万美元，2020-2030）

第 9 章拉丁美洲霍乱疫苗市场（单位：百万美元，2020-2030 年）

第 10 章中东和非洲霍乱疫苗市场（单位：百万美元，2020-2030 年）

第11章公司简介

  • Astellas Pharma, Inc.
  • Sonofi
  • Emergent BioSolutions, Inc.（PaxVax, Inc.）
  • Valneva SE
  • Eubiologics Co. Ltd.
  • GlaxoSmithKline plc（GSK）
  • Merck & Co., Inc.
  • Celldex Therapeutics, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Takeda Pharmaceutical Co. Ltd
  • Johnson & Johnson（Crucell）
Product Code: 137520-08-22

Global cholera vaccines market is anticipated to grow significantly with a CAGR of 10% during forecast period due to rising government initiatives in immunization program and growing incidence of cholera particularly in developing countries in Asia and Africa would drive the growth of cholera vaccines market globally.

Cholera is an infection of the small intestine by strains of the bacterium Vibrio cholera, which can cause death of the patient if left untreated. According to the World Health Organization (WHO) every year there are 1.3 to 4.0 million cases of cholera, and 21,000 to 143,000 deaths worldwide; it is affected primarily in Africa, South and Southeast Asia, and South Americas. Some factors such as higher prevalence of cholera in some African and south Asian countries and government initiative in immunization program are prime factors that driving the growth of cholera vaccines market globally. For the purpose of study market is segmented on the basis of product type such as dukoral, shanchol, vaxchora and others vaccines and geography. It is studied that, there are three WHO-prequalified, killed, whole-cell oral cholera vaccines are currently extensively use in market; among these Dukoral was observed as largest revenue contributing segment because it is the prequalified by World Health Organization (WHO) and has been licensed in more than 60 countries and it prevent diarrhea caused by Vibrio cholera and heat-labile toxin producing enterotoxigenic Escherichia coli (ETEC) are primarily driving the growth of Dukoral market globally.

For the purpose of this study, the global cholera vaccines market is regionally categorized into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa markets. These regional markets are further sub-segmented into top country level markets that majorly determine the regional industry trends. Among the considered regional markets, Asia Pacific currently dominates the global cholera vaccines market because large number of affected populations in South-East Asian countries and government initiatives in immunization program are prime factors that driving the market growth in Asia Pacific. However, it is estimated that North America will show the highest growth during forecast period and growth will mainly fuel by a new approved oral vaccine Vaxchora, as it is the only vaccine available in the United States for protection against cholera.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global cholera vaccines market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global cholera vaccines market. This report concludes with company profiles section that highlights major information about the key players engaged in global cholera vaccines market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.

It is studied that in the base year 2021, Dukoral held largest market share, due to some factors such as it is the only approved cholera vaccine available for European, Canadian and Australian travelers, it prevents diarrhea caused by Vibrio cholera and heat-labile toxin producing enterotoxigenic Escherichia coli (ETEC), it is the prequalified by World Health Organization (WHO) and has been licensed in more than 60 countries are primarily driving the growth of Dukoral market. On the other hand Vaxchora will expected to show significant growth during forecast period due to government recommendation for use in adults 18 through 64 years of age traveling to cholera-affected areas, it is the only vaccine available in the United States for protection against cholera and the only single dose vaccine for cholera currently licensed anywhere in the world these factors would expected to drive the market during forecast period.

Asia Pacific Dominates the market

In the base 2021, Asia Pacific was observed as the largest market for cholera vaccines because large pool of patients suffering with cholera, increasing healthcare awareness, government initiatives in treatment and awareness program are primarily driving the market growth in Asia Pacific. On the other hand North America expected to show fastest growth during forecast period because Vaxchora is the only vaccine available in the United States for protection against cholera and recommended use in adults 18 through 64 years of age traveling to cholera-affected areas would expected to assist the market growth in North America.

According to World Health Organization (WHO), cholera represents an estimated burden of 1.4 to 4.0 million cases, and 21,000 to 143,000 deaths per year worldwide. For the purpose of this study, the global cholera market is regionally categorized as North America, Europe, Asia Pacific, LATAM and MEA; among the considered regional markets North America is expected to dominate the cholera market during forecast period due to higher healthcare awareness among general population, government initiatives in treatment and awareness program, higher cost of vaccines and presence of key manufacturer would drive the market growth in North America, recently approved vaxchora would primarily assist market growth in North America. Centers for Disease Control and Prevention (CDC) recommendation for travelers to cholera-affected regions would fuel the market growth in United States. On the other hand, Asia Pacific is currently dominating the Cholera vaccines market due to increasing awareness of immunization, higher number of targeted population and government initiatives in awareness program are primarily driving the market growth in Asia Pacific.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cholera Vaccines market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Cholera Vaccines market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Product

Dukoral

Shanchol

Vaxchora

Others

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Cholera Vaccines market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Cholera Vaccines market?

Which is the largest regional market for Cholera Vaccines market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Cholera Vaccines market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Cholera Vaccines market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Cholera Vaccines Market
  • 2.2. Global Cholera Vaccines Market, By Product, 2021 (US$ Million)
  • 2.3. Global Cholera Vaccines Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Cholera Vaccines Market: Competitive Analysis

  • 3.1. Market Positioning of Key Cholera Vaccines Market Vendors
  • 3.2. Strategies Adopted by Cholera Vaccines Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Cholera Vaccines Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Cholera Vaccines Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Dukoral
    • 5.3.2. Shanchol
    • 5.3.3. Vaxchora
    • 5.3.4. Others

6. North America Cholera Vaccines Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
  • 6.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

7. UK and European Union Cholera Vaccines Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
  • 7.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

8. Asia Pacific Cholera Vaccines Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
  • 8.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

9. Latin America Cholera Vaccines Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
  • 9.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

10. Middle East and Africa Cholera Vaccines Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
  • 10.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. Astellas Pharma, Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Sonofi
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Emergent BioSolutions, Inc. (PaxVax, Inc.)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Valneva SE
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Eubiologics Co. Ltd.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. GlaxoSmithKline plc (GSK)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Merck & Co., Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Celldex Therapeutics, Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Mitsubishi Tanabe Pharma Corporation
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Takeda Pharmaceutical Co. Ltd
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Johnson & Johnson (Crucell)
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 2 North America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 3 U.S. Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 4 Canada Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 5 Rest of North America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 7 UK Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 8 Germany Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 9 Spain Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 10 Italy Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 11 France Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 12 Rest of Europe Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 13 Asia Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 14 China Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 15 Japan Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 16 India Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 17 Australia Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 18 South Korea Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 19 Latin America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 20 Brazil Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 21 Mexico Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 22 Rest of Latin America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 23 Middle East and Africa Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 24 GCC Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 25 Africa Cholera Vaccines Market By Product, 2020-2030, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Cholera Vaccines Market By Product, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Cholera Vaccines Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Cholera Vaccines Market: Quality Assurance
  • FIG. 5 Global Cholera Vaccines Market, By Product, 2021
  • FIG. 6 Global Cholera Vaccines Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Cholera Vaccines Market, 2021
  • FIG. 8 Market Positioning of Key Cholera Vaccines Market Players, 2021
  • FIG. 9 Global Cholera Vaccines Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Cholera Vaccines Market, By Product, 2021 Vs 2030, %
  • FIG. 11 U.S. Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 18 France Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 20 China Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 22 India Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Cholera Vaccines Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Cholera Vaccines Market (US$ Million), 2020 - 2030